Epigenetic Therapies Start Operating Outside the Lines

by EpicentRx | Dec 3, 2021 | Media

Genetic Engineering and Biotechnology News

World Vaccine & Immunotherapy, World Antiviral Congress 2021

by EpicentRx | Nov 30, 2021 | Conferences

November 2021, San Diego, California Oral Presentation: AdAPT-001, an oncolytic adenovirus armed with a TGF-beta “trap” fusion protein

EpicentRx Granted New Composition of Matter Patent for Its TGF-ß Trap Fusion Protein

by EpicentRx | Nov 22, 2021 | 2021, Press Releases

La Jolla, Calif., Nov. 22, 2021 – EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent...

Initial clinical and advanced imaging outcomes from a multi-institutional phase 1 dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases

by EpicentRx | Oct 28, 2021 | Journal Publications

Kim M, Parmar H, Aryal M, Schipper M, Devasia T, Kesari S, Morikawa A, et al. Society for NeuroOncology (SNO) 23rd Annual Meeting, Nov 15th-18th 2018, New Orleans, LA

RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment

by EpicentRx | Oct 28, 2021 | Journal Publications

ASCO-SITC Clinical Immuno-Oncology Symposium, Feb 28th – Mar 2nd 2019